Immunological off-target effects of standard treatments in gastrointestinal cancers
about
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaOncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.Immunological landscape and immunotherapy of hepatocellular carcinoma.Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.The case for immune-based approaches in biliary tract carcinoma.Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy?Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
P2860
Q28069864-8BE52004-60CE-49F2-81C1-37F3681B1888Q33579883-69A9D1B4-8800-46F0-9EB0-AA8CCC128F84Q36409532-5E4859B7-C6A4-4170-A3E1-A86169C29262Q38349665-28C88279-3E58-4A0E-891F-E562F7F2B6CDQ38611895-7586C5F8-590C-451F-9AB6-EED17E9F1079Q38733637-FE135899-C685-42A7-ACD9-1AE853B9EAFCQ38833922-03373B99-2A1B-4164-8AB6-57A0822F9B85Q42341966-131724D9-060C-48C1-8BED-387B78F108B4Q45072406-52DDC0C0-344A-48CD-8461-D056A91AA691Q47146426-53D3E221-13F9-47E8-BB21-FD956D08C12CQ50956087-3F4DF4F1-BA57-4585-9108-48CF3864E81CQ51534898-53444AD1-B033-4E1D-81E0-2404CC56FD3DQ55240544-1B463E90-09F8-431D-93AC-59FB0FC584E1
P2860
Immunological off-target effects of standard treatments in gastrointestinal cancers
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Immunological off-target effects of standard treatments in gastrointestinal cancers
@en
Immunological off-target effects of standard treatments in gastrointestinal cancers.
@nl
type
label
Immunological off-target effects of standard treatments in gastrointestinal cancers
@en
Immunological off-target effects of standard treatments in gastrointestinal cancers.
@nl
prefLabel
Immunological off-target effects of standard treatments in gastrointestinal cancers
@en
Immunological off-target effects of standard treatments in gastrointestinal cancers.
@nl
P2860
P356
P1433
P1476
Immunological off-target effects of standard treatments in gastrointestinal cancers
@en
P2093
P2860
P356
10.1093/ANNONC/MDT349
P577
2013-11-07T00:00:00Z